Clinical efficacy of immunotherapy combined with targeted therapy for postoperative recur-rent hepatocellular carcinoma
10.3760/cma.j.cn115610-20220908-00502
- VernacularTitle:免疫联合靶向治疗肝癌术后复发的临床疗效
- Author:
Jinmao LIAO
1
;
Huilin YANG
;
Zheng ZHANG
Author Information
1. 湖南师范大学附属第一医院（湖南省人民医院）肝病内科，长沙 410002
- Keywords:
Liver neoplasms;
Immunotherapy;
Targeted therapy;
Combination therapy;
Radiation therapy
- From:
Chinese Journal of Digestive Surgery
2022;21(S1):41-44
- CountryChina
- Language:Chinese
-
Abstract:
Systemic therapy is the preferred treatment option for advanced primary hepatic carcinoma, and the results of clinical study IMbrave150 suggesting the superiority of atezolizumab combined with bevacizumab for the treatment of hepatocellular carcinoma. The authors introduce the clinical experience of one patient with postoperative recurrent primary hepatic carcinoma who was treated with atezolizumab plus bevacizumab followed by radiotherapy. The results reveal that the efficacy as stable disease during immunotherapy combination of targeted therapy and partial response after radiotherapy, and the patient tolerating well with a high quality of life.
